Based on previous neuropathological results17, 18 and recent molecular imaging data19, 20 showing a greater burden of tau pathology in the temporal lobe in LBD+AD compared to LBD−AD, we hypothesized that LBD+AD patients would have greater cortical thinning in temporal neocortex than LBD−AD, and that regional cortical thinning would correlate most closely with regional quantitative burden of tau pathology. The gene discussed is MAPT; the disease is Alzheimer disease.